BioCentury
ARTICLE | Clinical News

Suberohydroxamic acid phenyl ester: Interim Phase II data

February 1, 2016 8:00 AM UTC

Interim data from 34 stage Ia-IIa CTCL patients in an open-label, U.S. Phase II trial showed that once-daily 1%, twice-daily 0.5% and twice-daily 1% topical SHAPE for 26 weeks led to 8 responses as me...